Combination of drug level measurement and parasite genotyping data for improved assessment of amodiaquine and sulfadoxine-pyrimethamine efficacies in treating Plasmodium falciparum malaria in Gabonese children

Antimicrobial Agents and Chemotherapy

Volumn 47, Issue 1, 2003, Pages 231-237

  Aubouy, Agnès ^a   Bakary, Mohamed ^b   Keundjian, Annick ^d   Mbomat, Bernard ^b   Makita, Jean Ruffin ^b   Migot Nabias, Florence ^a,f   Cot, Michel ^c   Le Bras, Jacques ^e   Deloron, Philippe ^a,c  

^a CENTRE INTERNATIONAL DE RECHERCHES MÉDICALES DE FRANCEVILLE   (Gabon)

^b Bakoumba Hospital   (Gabon)

^c INSTITUT DE RECHERCHE POUR LE DÉVELOPPEMENT   (France)

^d SERVICE DE SANTÉ DES ARMÉES   (France)

^e BICHAT HOSPITAL   (France)

^f INSTITUT DE RECHERCHE POUR LE DÉVELOPPEMENT   (Senegal)

Author keywords

[No Author keywords available]

Indexed keywords

AMODIAQUINE; CHLOROQUINE; DEETHYLAMODIAQUINE; FANSIDAR; MEROZOITE SURFACE PROTEIN 1; MEROZOITE SURFACE PROTEIN 2; PYRIMETHAMINE; SULFADOXINE;

ARTICLE; CHILD; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; GABON; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALARIA FALCIPARUM; MALE; MEASUREMENT; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL; TREATMENT OUTCOME; WORLD HEALTH ORGANIZATION;

AMODIAQUINE; ANIMALS; CHILD; CHILD, PRESCHOOL; DRUG COMBINATIONS; FEMALE; GABON; GENOTYPE; HUMANS; INFANT; MALARIA, FALCIPARUM; MALE; PLASMODIUM FALCIPARUM; PYRIMETHAMINE; SULFADOXINE; TREATMENT OUTCOME;

EID: 12244270403     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.47.1.231-237.2003     Document Type: Article

References (40)

1. Adjuik, M., P. Agnamey, A. Babiker, S. Borrmann, P. Brasseur, M. Cisse, F. Cobelens, S. Diallo, J. F. Faucher, P. Garner, S. Gikunda, P. G. Kremsner, S. Krishna, B. Lell, M. Loolpapit, P. B. Matsiegui, M. A. Missinou, J. Mwanza, F. Ntoumi, P. Olliaro, P. Osimbo, P. Rezbach, E. Some, and W. R. Taylor. 2002. Amodiaquine-artesunate versus amodiaquine for uncomplicated Plasmodium falciparum malaria in African children: a randomized, multicentre trial. Lancet 359:1365-1372.
2. Al-Yaman, F., B. Genton, J. C. Reeder, R. F. Anders, and M. P. Alpers. 1997. Evidence that recurrent Plasmodium falciparum infection is caused by recrudescence of resistant parasites. Am. J. Trop. Med. Hyg. 56:436-439.
3. Basco, L., and P. Ringwald. 2000. Chimiorésistance du paludisme: problèmes de la définition et de l'approche technique. Santé 10:47-50.
4. Basco, L. K., A. Same-Ekobo, V. F. Ngane, M. Ndounga, T. Metoh, P. Ringwald, and G. Soula. 2002. Therapeutic efficacy of sulfadoxine-pyrimethamine, amodiaquine and the sulfadoxine-pyrimethamine-amodiaquine combination against uncomplicated Plasmodium falciparum malaria in young children in Cameroon. Bull. W. H. O. 80:538-545.
5. Bojang, K. A., G. Schneider, S. Forck, S. K. Obaro, S. Jaffar, M. Pinder, J. Rowley, and B. M. Greenwood. 1998. A trial of Fansidar plus chloroquine or Fansidar alone for the treatment of uncomplicated malaria in Gambian children. Trans. R. Soc. Trop. Med. Hyg. 92:73-76.
6. Brasseur, P., R. Guiguemde, S. Diallo, V. Guiyedi, M. Kombila, P. Ringwald, and P. Olliaro. 1999. Amodiaquine remains effective for treating uncomplicated malaria in west and central Africa. Trans. R. Soc. Trop. Med. Hyg. 93:645-650.
7. Brooks, D. R., P. Wang, M. Read, W. M. Watkins, P. F. G. Sims, and J. E. Hyde. 1994. Sequence variation of the hydroxymethyldihydropterin pyrophosphokinase: dihydropteroate synthetase gene in lines of the human malaria parasite. Plasmodium falciparum, with differing resistance to sulfadoxine. Eur. J. Biochem. 2:397-405.
8. Daubersies, P., S. Sallenave-Sales, S. Magne, J. F. Trape, H. Contamin, T. Fandeur, C. Rogier, O. Mercereau-Puijalon, and P. Druilhe. 1996. Rapid turnover of Plasmodium falciparum populations in asymptomatic individuals living in a high transmission area. Am. J. Trop. Med. Hyg. 54:18-26.
9. Deloron, P., J. Mayombo, A. Le Cardinal, J. Mezui-Me-Ndong, C. Bruzi-Baert, F. Lekoulou, and N. Elissa. 2000. Sulfadoxine-pyrimethamine for the treatment of Plasmodium falciparum malaria in Gabonese children. Trans. R. Soc. Trop. Med. Hyg. 94:188-190.
10. Deloron, P., J. D. Sexton, L. Bugilimfura, and C. Sezibera. 1988. Amodiaquine and sulfadoxine-pyrimethamine as treatment for chloroquine-resistant Plasmodium falciparum in Rwanda. Am. J. Trop. Med. Hyg. 38:244-248.
11. Edstein, M. 1984. Quantification of antimalarial drugs. I. Simultaneous measurement of sulphadoxine, N4-acetylsulphadoxine and pyrimethamine in human plasma. J. Chromatogr. 305:502-507.
12. Edstein, M. 1984. Quantification of antimalarial drugs. II. Simultaneous measurement of dapsone, monoacetyldapsone and pyrimethamine in human plasma. J. Chromatogr. 307:426-431.
13. Elissa, N., S. Karch, P. Bureau, B. Ollomo, M. Lawoko, P. Yangari, B. Ebang, and A. J. Georges. 1999. Malaria transmission in a region of savannaforest mosaic, Haut-Ogooue, Gabon. J. Am. Mosq. Control Assoc. 15:15-23.
14. Farnert, A., G. Snounou, I. Rooth, and A. Bjorkman. 1997. Daily dynamics of Plasmodium falciparum subpopulations in asymptomatic children in a holoendemic area. Am. J. Trop. Med. Hyg. 56:538-547.
15. Fevre, E. M., and G. Barnish. 1999. Malaria-treatment policies: when and how should they be changed? Ann. Trop. Med. Parasitol. 93:549-560.
16. Foote, S. J., D. Galatas, and A. F. Cowman. 1990. Amino acids in the dihydrofolate reductase-thymidylate synthase gene of Plasmodium falciparum involved in cycloguanil resistance differ from those involved in pyrimethamine resistance. Proc. Natl. Acad. Sci. USA 87:3014-3017.
17. Foster, S. 1994. Economic prospects for a new antimalarial drug. Trans. R. Soc. Trop. Med. Hyg. 88(Suppl. 1):S55-S56.
18. Gorissen, E., G. Ashruf, M. Lamboo, J. Bennebroek, S. Gikunda, G. Mbaruku, and P. A. Kager. 2000. In vivo efficacy study of amodiaquine and sulfadoxine/pyrimethamine in Kibwezi, Kenya and Kigoma, Tanzania. Trop. Med. Int. Health 5:459-463.
19. Kamya, M. R., G. Dorsey, A. Gasasira, G. Ndeezi, J. N. Babirye, S. G. Staedke, and P. J. Rosenthal. 2001. The comparative efficacy of chloroquine and sulfadoxine-pyrimethamine for the treatment of uncomplicated falciparum malaria in Kampala, Uganda. Trans. R. Soc. Trop. Med. Hyg. 95:50-55.
20. Miller, L. H., T. Roberts, M. Shahahuddin, and T. F. McCutchan. 1993. Analysis of sequence diversity in the Plasmodium falciparum merozoite surface protein-1 (MSP-1). Mol. Biochem. Parasitol. 59:1-14.
21. Muller, O., M. B. van Hensbroek, S. Jaffar, C. Drakeley, C. Okorie, D. Joof, M. Pinder, and B. Greenwood. 1996. A randomized trial of chloroquine, amodiaquine and pyrimethamine-sulphadoxine in Gambian children with uncomplicated malaria. Trop. Med. Int. Health. 1:124-132.
22. Ogutu, B. R., B. L. Smoak, R. W. Nduati, D. A. Mbori-Ngacha, F. Mwathe, and G. D. Shanks. 2000. The efficacy of pyrimethamine-sulfadoxine (Fansidar) in the treatment of uncomplicated Plasmodium falciparum malaria in Kenyan children. Trans. R. Soc. Trop. Med. Hyg. 94:83-84.
23. Oiliaro, P., C. Nevill, J. LeBras, P. Ringwald, P. Mussano, P. Garner, and P. Brasseur. 1996. Systematic review of amodiaquine treatment in uncomplicated malaria. Lancet 348:1196-1201.
24. Phillips-Howard, P. A., and L. J. West. 1990. Serious adverse drug reactions to pyrimethamine-sulphadoxine, pyrimethamine-dapsone and to amodiaquine in Britain. J. R. Soc. Med. 83:82-85.
25. Plowe, C. V., A. Djimde, M. Bouare, O. Doumbo, and T. E. Wellems. 1995. Pyrimethamine and proguanil resistance-conferring mutations in Plasmodium falciparum dihydrofolate reductase: polymerase chain reaction methods for surveillance in Africa. Am. J. Trop. Med. Hyg. 52:565-568.
26. Pussard, E., F. Verdier, and M. C. Blayo. 1986. Simultaneous determination of chloroquine, amodiaquine and their metabolites in human plasma, red blood cells, whole blood and urine by column liquid chromatography. J. Chromatogr. 374:111-118.
27. Radloff, P. D., J. Philipps, M. Nkeyi, D. Hutchinson, and P. G. Kremsner. 1996. Atovaquone and proguanil for Plasmodium falciparum malaria. Lancet 347:1511-1514.
28. Ranford-Cartwright, L. C., J. Taylor, T. Umasunthar, L. H. Taylor, H. A. Babiker, B. Lell, J. R. Schmidt-Ott, L. G. Lehman, D. Walliker, and P. G. Kremsner. 1997. Molecular analysis of recrudescent parasites in a plasmodium falciparum drug efficacy trial in Gabon. Trans. R. Soc. Trop. Med. Hyg. 91:719-724.
29. Ringwald, P., and L. K. Basco. 1999. Comparison of in vivo and in vitro tests of resistance in patients treated with chloroquine in Yaounde, Cameroon. Bull. W. H. O. 77:34-43.
30. Ringwald, P., A. Keundjian, A. Same Ekobo, and L. K. Basco. 2000. Chimiorésistance de Plasmodium falciparum en milieu urbain à Yaoundé, Cameroun. 2. Evaluation de l'efficacité de l'amodiaquine et de l'association sulfadoxine-pyriméthamine pour le traitement de l'accès palustre simple à Plasmodium falciparum à Yaoundé, Cameroun. Trop. Med. Int. Health. 5:620-627.
31. Sibley, C. H., J. E. Hyde, P. F. Sims, C. V. Plowe, J. G. Kublin, E. K. Mberu, A. F. Cowman, P. A. Winstanley, W. M. Watkins, and A. M. Nzila. 2001. Pyrimethamine-sulfadoxine resistance in Plasmodium falciparum: what next? Trends Parasitol. 17:582-588.
32. Smythe, J. A., M. G. Peterson, R. L. Coppel, A. J. Saul, D. J. Kemp, and R. F. Anders. 1990. Structural diversity in the 45-kilodalton merozoite surface antigen of Plasmodium falciparum. Mol. Biochem. Parasitol. 39:227-234.
33. Snewin, V. A., M. Herrera, G, Sanchez, A. Scherf, G. Langsley, and S. Herrera. 1991. Polymorphism of the alleles of the merozoite surface antigens MSA1 and MSA2 in Plasmodium falciparum wild isolates from Colombia. Mol. Biochem. Parasitol. 49:265-275.
34. Staedke, S. G., M. R. Kamya, G. Dorsey, A. Gasasira, G. Ndeezi, E. D. Charlebois, and P. J. Rosenthal. 2001. Amodiaquine, sulfadoxine/pyrimethamine, and combination therapy for treatment of uncomplicated falciparum malaria in Kampala, Uganda: a randomised trial. Lancet 358:368-374.
35. Stott, G. J., and S. M. Lewis. 1995. A simple and reliable method for estimating haemoglobin. Bull. W. H. O. 73:369-373.
36. Su, X. Z., L. A. Kirkman, H. Fujioka, and T. E. Wellems. 1997. Complex polymorphisms in ∼ 330 kDa protein are linked to chloroquine-resistant P. falciparum in Southeast Asia and Africa. Cell 91:593-603.
37. World Health Organization. 1996. Assessment of therapeutic efficacy of antimalarial drugs for uncomplicated falciparum malaria in areas with intense transmission. Report no. MAL/96.1077. World Health Organization, Geneva, Switzerland.
38. World Health Organization. 2000. Communicable diseases cluster: severe falciparum malaria. Trans. R. Soc. Trop. Med. Hyg. 94(Suppl. 1):S1-S90.
39. World Health Organization. 2002. Monitoring antimalarial drug resistance. Report no. CDS/CSR/EPH/2002.17. World Health Organization, Geneva, Switzerland.
40. Zwetyenga, J., C. Rogier, A. Spiegel, D. Fontenille, J. F. Trape, and O. Mercereau-Puijalon. 1999. A cohort study of Plasmodium falciparum diversity during the dry season in Ndiop, a Senegalese village with seasonal, mesoendemic malaria. Trans. R. Soc. Trop. Med. Hyg. 93:375-380.